Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2008
03/05/2008CN100372524C Amphotericin B nano preparation
03/05/2008CN100372519C Medicine filling method of levonorgestrel silica gel stick
03/04/2008US7340299 Methods of indirectly stimulating the vagus nerve to achieve controlled asystole
03/04/2008US7339079 E.g., N-methyl-O-benzyl-tyramine, 3,5,3',5'-tetraiodothyroethanolamine; antagonist of a G protein coupled receptor and a trace amine receptor; antidepressants; nervous system disorders; antidiabetic agents; antiarrhymia disorders; glandular disorders of the thyroid; congestive heart failure; analgesics
03/04/2008US7339078 Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
03/04/2008US7339065 Design and synthesis of optimized ligands for PPAR
03/04/2008US7339064 Benzimidazole compound crystal
03/04/2008US7339063 Quinolyl organic germanium ester and the synthesis method thereof
03/04/2008US7339061 3-(4-oxo-4H-chromen-2-yl)-(1H)-quinolin-4-one derivatives, method for preparing same and pharmaceutical compositions containing same
03/04/2008US7339059 Benzofuran-2-yl-carbonyl- and indol-2-yl-carbonyl-trans-2,5-dimethyl-piperazine derivatives; rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, asthma; inhibit the interaction between inflammatory chemokines and their receptor
03/04/2008US7339058 Process for the preparation of N-([1,2,4]triazolopyrimidin-2-yl)aryl sulfonamides
03/04/2008US7339053 4′-C-substituted-2-haloadenosine derivative
03/04/2008US7339051 Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
03/04/2008US7339047 Comprises nucleotide sequences coding interleukin-1b converting enzyme ligand for use in diagnosis, prevention and treatment of autoimmune, connective tissue and crohn's diseases
03/04/2008US7338979 Depigmentation agents
03/04/2008US7338977 for the treatment of viral infection, particularly HIV-1 infection; non-brominated, partially alkylated pyrogallol calixarene type compounds and derivatives thereof
03/04/2008US7338976 Administering heterocyclic esters and amides: 3-phenyl-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine)carboxylate; 3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate; immunosuppressants; affinity for an FK binding protein-type immunophilin
03/04/2008US7338975 Lactams as modulators of chemokine receptor activity
03/04/2008US7338974 Macrocyclic diaminopropanes as beta-secretase inhibitors
03/04/2008US7338973 7-benzyloxy-3-methoxy-10H-benzo[4,5]furo[3,2-b]indole; postmenopausal syndrome; side effect reduction; selectivity; hot flashes, vaginal dryness, endometriosis, hormone sensitive cancers, contraceptives
03/04/2008US7338972 Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
03/04/2008US7338971 Treatment of inflammatory, cancer, and thrombosis disorders
03/04/2008US7338970 Containing microcrystalline cellulose, lubricant, colloidal silica and lactose; use in treating depression, Parkinson's disease and severe psychotic disorders, such as schizophrenia and schizoaffective disorders.
03/04/2008US7338969 Acyclic, aromatic, heteroaromatic and cyclic ring containing amido-derivatives, useful as antibacterial agent; inhibition of formation of biofilms in personal hygiene articles, toileteries, cosmetics and in industrial settings like ship hulls, food processing systems, oil recovery or paper making plants
03/04/2008US7338968 inhibitors of IL-8 receptor binding; cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke, ischemia reperfusion injury, pain; novel antiinflammatory, antitumor agents
03/04/2008US7338967 3-(2,6-Dichlorophenyl)-4-[(3-pyridyl)hydroxymethyl]-5-trimethysilylisoxazole; crop protection agents to combat or prevent fungal infestations, or to control other pests such as weeds, insects, or acarids
03/04/2008US7338966 Substituted oxindole derivatives as tyrosine kinase inhibitors
03/04/2008US7338965 Enzyme inhibitors of beta-secretase which cleaves amyloid precursor protein present in Alzheimer's disease; Trisomy 21 (Down's Syndrome); Hereditary Cerebral Hemorrhage; cognition activators; Parkinson's disease
03/04/2008US7338964 2-(2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl)-6-amino-9-methyl-1-deazapurine; antiinflammatory, neuroleptic agent, antiallergens, neuroprotectant and antidepressant, cognition activator; improved bioavailability, without a ribose moiety; prodrugs with primary or secondary amino or hydroxy groups
03/04/2008US7338963 blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 3-(4-methoxy-phenyl)-5-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3,5,6,7-tetrahydro-[1,2,3]triazolo4,5-c]pyridin-4-one; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis
03/04/2008US7338962 Spirocyclic heterocyclic derivatives and methods of their use
03/04/2008US7338961 Sphingosine kinase inhibitors
03/04/2008US7338960 {[2-Methyl-4-({[4'-(trifluoromethyl)-3-biphenylyl]methyl}thio)phenyl]oxy}acetic acid; adipogenic signalling cascade and lipid homeostasis; increase High Density Lipoproteins; hypotensive agent; Syndrome X, obesity, insulin resistance, cardiovascular disorder
03/04/2008US7338959 N2-isopropyl-N5,1-dimethyl-N5-[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]-1H-benzimidazole-2,5-diamine; vascular endothelial growth factor (VEGF) receptor-2 and tyrosine kinase containing Ig and EGF homology domains (TIE) -2 inhibitor; antiproliferation and antihypoxic agent
03/04/2008US7338958 Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents
03/04/2008US7338957 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs
03/04/2008US7338956 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
03/04/2008US7338955 Medicament for treatment of neuropathies
03/04/2008US7338954 Compounds useful as motilin agonists and method
03/04/2008US7338953 Administering racemic reboxetine or a salt thereof for inhibition of norepinephrine reuptake
03/04/2008US7338952 N-[2-[4-[(4-chlorophenyl)ethynyl]-2-methylphenoxy]-1-methylethyl]-1,4-benzenedimethanamine; phosphorylation, polymorphonuclear leukocyte, macrophage, lipopolysaccharide, tumor necrosis factor- alpha, cytokine IFN- gamma, interleukin-2 mediated disorders ; arthritis, osteoarthritis, Alzheimer's disease
03/04/2008US7338951 N-{2-[2-(3,4-Dimethoxy-phenyl)-ethoxy]-6-morpholin-4-yl-pyridin-4-yl}-N'-(1 H-indol-3-ylmethylene)-hydrazine; interleukin IL-12 overproduction-related disorder; antiinflammatory agent; autoimmune diseases: multiple sclerosis, sepsis, neuropathies, cirrhosis, hepatitis, diabetes, arthritis
03/04/2008US7338950 Amide compounds as ion channel ligands and uses thereof
03/04/2008US7338949 Mycobacterial inhibitors
03/04/2008US7338948 Use of quetiapine
03/04/2008US7338947 monocyte chemotactic proteins (MCP)-1 receptor antagonist or agonist; 2-{1-[(1,2-cis)-2-(4-Methylsulfanyl-benzoylamino)-cyclohexyl]-2-oxo-pyrrolidin-3-ylcarbamoyl}-4-trifluoromethyl-phenyl)-carbamic acid tert-butyl ester; antiinflammatory agent, antiallergen; asthma, rheumatoid arthritis, atherosclerosis
03/04/2008US7338946 Indazolium trans-[tetrachlorobis(1H-indazol)-ruthenate(III)]; easily water-soluble; exhibits a high effectiveness in the treatment of cancer illnesses
03/04/2008US7338943 Hyaluronic acid in soft gel form
03/04/2008US7338942 Sustained released glucosamine in high molecular weight cellulose; antiarthritic agents ; side effect reduction
03/04/2008US7338941 Identifying a mammal; administering isovitexin or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof
03/04/2008US7338940 Heterocyclic alcohols such as 2-deoxy-D-glucose or 5-thio-D-glucose, used as anticarcinogenic agents or angiogenesis inhibitors; glycolysis antagonists
03/04/2008US7338931 Administering a hyaluronic acid and an insulin for treating diabetes; structure compacted due to the passing of the structure over its point of collapse with buried polar groups and a minimum size; the hyaluronic acid surrounds the insulin
03/04/2008US7338672 Administering Leucojum aestivum plant extract containing galanthamine for improving Estrogen-deficiency related cognitive dysfunction
03/04/2008US7338667 Active material in hydrophilic polymer matrix
03/04/2008US7338666 Methods for modulating the axonal outgrowth of central nervous system neurons
03/04/2008US7338663 Expandable osmotic composition and coating suspension
03/04/2008US7338660 Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
03/04/2008US7338658 Chimeric antibody specific to human CD4 which comprises the variable heavy and light chain sequences of an Old World monkey monoclonal antibody produced against human CD4 and human constant heavy and light domain sequences
03/04/2008US7338655 Generating a recombinant viral or plasmid vector; transfecting in vitro a population of chondrocytes with recombinant vector, transplanting transfected chondrocytes without scaffolding by intraarticular injection to an osteoarthritic joint space for regenerating hyaline cartilage
03/04/2008US7338651 Multi-use multimodal imaging chelates
03/04/2008CA2329210C Process for preparation of enantiomerically pure n-methyl-n-[(1s)-1-phenyl-2((3s)-3-hydroxypyrrolidin-1-yl) ethyl]-2,2-diphenylacetamide
03/01/2008CA2598060A1 Methods and compositions for the treatment and prevention of cancer
03/01/2008CA2595839A1 Composition based on salts of hyaluronic acid for treating epithelial lesions
03/01/2008CA2558465A1 Fat metabolism improving agent
02/2008
02/29/2008CA2558110A1 Composition and method for enhancing or promoting the activity of insulin, enhancing skeletal muscle growth, reducing skeletal muscle loss, and increasing the energy supply to skeletal muscle
02/28/2008WO2008024981A1 Piperazine-substituted benzothiophenes for treatment of mental disorders
02/28/2008WO2008024979A2 Methods utilizing cell-signaling lysophospholipids
02/28/2008WO2008024974A1 Pyrimidine and pyrazine derivatives
02/28/2008WO2008024963A1 Benzene, pyridine, and pyridazine derivatives
02/28/2008WO2008024961A1 Dihydropyridazine, tetrahydropyridine, chromanone, and dihydronaphthalenone derivatives as heat-shock protein 90 inhibitors
02/28/2008WO2008024945A1 Indazole derivatives that inhibit trpv1 and uses thereof
02/28/2008WO2008024930A2 Intrathecal administration of triptan compositions to treat non-migraine pain
02/28/2008WO2008024922A2 8-hydroxyquinoline compounds and methods thereof
02/28/2008WO2008024914A2 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
02/28/2008WO2008024893A2 Derivatives of uric and thiouric acid for oxidative stress-related diseases
02/28/2008WO2008024846A2 Brimonidine and timolol compositions
02/28/2008WO2008024787A1 Method of treatment or prophylaxis of depression
02/28/2008WO2008024784A1 Alkylsulfonamide-substituted triazoles as matrix metalloprotease inhibitors
02/28/2008WO2008024776A1 Inhibiting jnk signaling promotes cns axon regeneration
02/28/2008WO2008024763A2 Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
02/28/2008WO2008024759A2 Immunomodulatory compounds that target and inhibit the py+3 binding site of tyrosene kinase p56 lck sh2 domain
02/28/2008WO2008024749A2 Methods and compositions for treating ischemic stroke
02/28/2008WO2008024746A1 4-substituted phenoxyphenylacetic acid derivatives
02/28/2008WO2008024734A2 Use of pkc inhibitors in particular indolylmaleimide derivatives in ocular diseases
02/28/2008WO2008024725A1 Aza-benzofuranyl compounds and methods of use
02/28/2008WO2008024724A1 Aza-benzothiophenyl compounds and methods of use
02/28/2008WO2008024715A2 Tonsillitis treatment
02/28/2008WO2008024700A2 Tonsillitis treatment
02/28/2008WO2008024660A2 Method of reducing neuronal cell damage
02/28/2008WO2008024634A1 Pyrimdine compounds useful as kinase inhibitors
02/28/2008WO2008024509A2 Cationic latex as a carrier for bioactive ingredients and methods for making and using the same
02/28/2008WO2008024494A2 Pharmacokinetically improved compounds
02/28/2008WO2008024492A2 Indolinone phenylaminopropanol derivatives and process for the preparation thereof
02/28/2008WO2008024484A1 Methods and compositions for treating cancer
02/28/2008WO2008024481A2 3,4-dihydro-2 (1h) - quinolinone and 2 (1h)-quinolinone derivatives
02/28/2008WO2008024456A2 Substituted acylanilides and methods of use thereof
02/28/2008WO2008024439A2 4-aminoquinazoline derivatives and methods of use thereof
02/28/2008WO2008024438A2 2-phenoxy pyrimidinone analogues
02/28/2008WO2008024435A2 Dendritic molecular intracellular transporters and methods of making and using same
02/28/2008WO2008024433A2 Haloalkyl-substituted pyrimidinone derivatives